WASHINGTON, D.C. - (Mealeys) In a divided ruling, the Federal Circuit U.S.
Court of Appeals today [August 16th] reversed a New York federal judge's determination that
composition claims related to isolated DNA molecules are patent-ineligible
products of nature and scientific principles pursuant to Section 101 of the
Patent Act (The Association for Molecular Pathology, et al. v. U.S. Patent
and Trademark Office and Myriad Genetics Inc., No. 10-1406, Fed. Cir.; See
8/6/12, Page 5).
The panel of Circuit Judges Alan D. Lourie, Kimberly A. Moore
and William C. Bryson, acting on remand from the U.S. Supreme Court, heard oral
arguments in the dispute less than one month ago.
"The district court in effect created a categorical rule
excluding isolated genes from patent eligibility. But the Supreme Court
has more than once cautioned that courts 'should not read into the patent laws
limitations and conditions which the legislature has not expressed and has
repeatedly rejected new categorical exclusions from § 101's scope,'" the
Federal Circuit wrote, citing Bilski v. Kappos (130 S. Ct. 3218, 3225
 [enhanced version available to lexis.com subscribers]; See 7/2/10, Page 4).
"Contrary to the conclusions of the district court and the
suggestions of Plaintiffs and some amici, § 101 applies equally to all
putative inventions, and isolated DNA is not and should not be considered a
special case for purposes of patent eligibility under existing law," the
appellate panel added.
Diagnostic Test Kits
The panel in July 2011 found that Myriad Genetics Inc.'s U.S.
patent No. 5,747,282 - which covers diagnostic test kits for mutations along
the BRCA1 and BRCA2 genes - is valid, over objections by the Association for Molecular Pathology,
which Myriad had accused of infringement in 2009 before U.S. Judge Robert W.
Sweet of the Southern District of New York. The association then appealed
the findings to the Supreme Court, which, in the interim, decided Mayo
Collaborative Services v. Prometheus Laboratories Inc. (No. 10-1150, U.S.
Sup. [enhanced version available to lexis.com subscribers]; See 12/19/11, Page 6). In that case, Supreme Court found that processes
claimed by a patent reciting laws of nature are not themselves patentable
absent the presence of "additional features" that "transform" natural
correlations into patentable applications.
After the decision, the Supreme Court granted the association's
petition for certiorari for the limited purpose of vacating and remanding
the dispute for reconsideration in light of Mayo. The Federal
Circuit in April announced that oral arguments would be held July 20.
Turning first to Myriad's composition claims, the appellate
panel reversed Judge Sweet, instead finding that isolated DNA molecules "are
not found in nature."
"They are obtained in the laboratory and are man-made, the
product of human ingenuity. While they are prepared from products of
nature, so is every other composition of matter. All new chemical or
biological molecules, whether made by synthesis or decomposition, are made from
natural materials. For example, virtually every medicine utilized by
today's medical practitioners, and every manufactured plastic product, is
either synthesized from natural materials (most often petroleum fractions) or
derived from natural plant materials. But, as such, they are different
from natural materials, even if they are ultimately derived from them.
The same is true of isolated DNA molecules," the Federal Circuit held.
While the parties, including the U.S. government, were unable to
agree on whether and to what degree isolated DNA molecules fall within the
exception for products of nature, the Federal Circuit was less uncertain.
"The challenged claims . . . whether limited to cDNAs
[complementary DNA] or not, are directed to patent-eligible subject matter
under § 101," the Federal Circuit wrote, because under the test espoused in Diamond
v. Chakrabarty (447 U.S. 303  [enhanced version available to lexis.com subscribers]), "the claims cover molecules that are
markedly different - have a distinctive chemical structure and identity - from
those found in nature."
"Under the statutory rubric of § 101, isolated DNA is a
tangible, man-made composition of matter defined and distinguished by its
objectively discernible chemical structure. Whether its unusual status as
a chemical entity that conveys genetic information warrants singular treatment
under the patent laws as the district court did is a policy question that we
are not entitled to address," the appellate panel added.
Not Naturally Occurring
Similarly, Judge Sweet's disposition of Myriad's method claim 20
relating to the screening of potential cancer therapeutics via changes in cell
growth rates of novel, man-made transformed cells is also subject to reversal,
according to the Federal Circuit. Noting that all parties agreed that
transformed cells arise from human effort, the appellate panel rejected the
association's claim that the claimed method preempts the basic scientific
principle that a slower growth rate in the presence of a potential therapeutic
compound suggests that the compound is a cancer therapeutic and that such a
claim is indistinguishable from what the Supreme Court held ineligible in Mayo.
"Claim 20 recites a method that comprises the steps of (1)
growing host cells transformed with an altered BRCA1 gene in the presence or
absence of a potential cancer therapeutic, (2) determining the growth rate of
the host cells with or without the potential therapeutic, and (3) comparing the
growth rate of the host cells. Claim 20 thus recites a screening method
premised on the use of 'transformed' host cells. Those cells, like the
patent-eligible cells in Chakrabarty, are not naturally occurring.
Rather, they are derived by altering a cell to include a foreign gene,
resulting in a man-made, transformed cell with enhanced function and
utility. The claim thus includes more than the abstract mental step of
looking at two numbers and 'comparing' two host cells' growth rates," the
Federal Circuit wrote.
With regard to method claims relating to the comparison of
certain DNA sequences, however, the appellate panel cited Mayo and
reaffirmed both Judge Sweet and the Federal Circuit's since-vacated 2011
ruling, finding that the methods claim only patent-ineligible abstract mental
Judge Moore authored a concurrence, in which she joined the
majority's holdings with regard to issues of standing and the patentability of
Myriad's method claims. In a dissent, Judge Bryson also indicated his
agreement with regard to the method claim but criticized the majority's
findings as they relate to isolated DNA.
"In my view, those claims are not directed to patentable subject
matter, and the court's decision, if sustained, will likely have broad
consequences, such as preempting methods for whole-genome sequencing, even
though Myriad's contribution to the field is not remotely consonant with such
"The essence of Myriad's argument in this case is to say that it
has not patented a human gene, but something quite different - an isolated
human gene, which differs from a native gene because the process of extracting
it results in changes in its molecular structure (although not in its genetic
code). We are therefore required to decide whether the process of
isolating genetic material from a human DNA molecule makes the isolated genetic
material a patentable invention. The court concludes that it does; I
conclude that it does not," Judge Bryson wrote.
is represented by Christopher Hansen, Steven R. Shapiro, Sandra S. Park, Aden
J. Fine and Lenora M. Lapidus of the American Civil Liberties Union Foundation
in New York and Daniel B. Ravicher and Sabrina
Y. Hassan of Public Patent Foundation, Benjamin N. Cardozo School of Law in New York. Myriad is
represented by Gregory Castanias of Jones Day in Washington.
Mealey's is now
available in eBook format!
Sign in with your Lexis.com ID to access Patent Law resources on Lexis.com or any of these Mathew Bender Patent Law publications.
Click here to order Patent Law treatises/resources and Mathew Bender publications.
View the LexisNexis
Catalog of Legal and Professional Publications
here for a list of available LexisNexis eBooks.
Click here to learn more about
For more information about LexisNexis products and solutions connect with us through our corporate site.